Full-Time

Vice President of Regulatory Sciences

Posted on 7/19/2025

Strand Therapeutics

Strand Therapeutics

51-200 employees

Develops programmable, long-acting mRNA therapeutics

Compensation Overview

$315k - $365k/yr

+ Bonus + Equity Incentives

Boston, MA, USA

In Person

Category
Legal & Compliance (1)
Requirements
  • Bachelor's degree in a scientific discipline required with a preference for a Masters, PharmD, PhD or other Advanced Degree preferred
  • 15-20+ years of regulatory strategy experience in biotech; experience working in a smaller, fast paced environment highly preferred
  • Excellent written and spoken communication skills
  • Agile and flexible with problem-solving and innovative mindset in developing regulatory strategy
  • Extensive experience with the development and preparation of regulatory submissions including briefing books, INDs, and BLAs (including expedited pathways) required
  • Regulatory experience within the field of oncology required, with mRNA and gene therapy experience being highly preferred
  • Experience with rare diseases is a plus
  • Proven track record of successfully partnering with and serving as the primary point of contact to regulatory agencies such as CBER is a must
  • Solid knowledge of FDA, EMA and ICH guidelines and regulations
  • Prior interactions and experience with global health authorities such as EMA, PMDA, and TGA is a plus
  • Strong project management skills, with proven track record of delivering high impact results
  • Collaborative mindset with strong interpersonal skills with the ability to interact and communicate effectively with individuals from multiple departments at all levels of the organization
  • Strong organizational and time management skills
Responsibilities
  • Responsible for management and leadership of Regulatory Affairs including Global Strategy, CMC, Operations, management of Regulatory Vendors, and build of the Regulatory Affairs function and processes
  • Responsible for developing and driving the regulatory strategy for clinical stage lead asset and other candidates at the pre-clinical development phase using and understanding the scientific principles that underly Strand’s technology
  • Bring regulatory innovation to Strand’s programmable mRNA-based therapeutics that supports efficient transition through clinical development
  • Serve as Strand’s point of contact for all regulatory interactions including the preparation and leading of meetings with global regulatory agencies
  • Establish positive relationships with regulatory agency personnel. Organize and manage participation in meetings and prepare internal teams for regulatory interactions. Negotiate with regulatory authorities regarding company submissions as relevant
  • Key thought partner to Research and Development in developing preclinical deliverables that lead to successful submissions in a timely manner
  • Provide regulatory oversight and guidance to project teams on compliance, health authority requirements, clinical study design, and overall strategy
  • Evaluate and implement emerging AI and digital technologies to streamline submission processes and enhance regulatory strategy and decision-making across regulatory functions
Desired Qualifications
  • Masters, PharmD, PhD or other Advanced Degree preferred
  • Experience working in a smaller, fast paced environment highly preferred
  • Regulatory experience within oncology with mRNA and gene therapy experience highly preferred
  • Experience with rare diseases is a plus
  • Prior interactions and experience with global health authorities such as EMA, PMDA, and TGA is a plus

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company Size

51-200

Company Stage

Series B

Total Funding

$256M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • STX-001 Phase 1 showed confirmed complete response and partial responses by April 2025.
  • $153M Series B from Regeneron, Lilly, Amgen funds STX-003 Phase 1 in 2026.
  • New CFO Kunal Bhatia and CMO Jason Luke strengthen leadership for Phase 2 transition.

What critics are saying

  • Regeneron's liblocalcin achieves 62% ORR in refractory melanoma, eroding STX-001 edge.
  • FDA clinical hold on self-replicating RNA like Gritstone's halts STX-001 by Q2 2026.
  • Eli Lilly enforces milestone repayment if STX-001 misses 20% ORR in Q4 2026 readout.

What makes Strand Therapeutics unique

  • STX-001 deploys programmable mRNA with logic circuits sensing diseased cells only.
  • Intratumoral STX-001 produces localized IL-12, activating immunity without systemic toxicity.
  • Platform enables cell-type specific, multi-functional mRNA therapies for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Strand Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Life Insurance

Unlimited Paid Time Off

Phone/Internet Stipend

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-4%
The Pharma Data
Aug 23rd, 2025
Strand Therapeutics Names Dr. Jason J. Luke as New Chief Medical Officer

Strand Therapeutics strengthens leadership with appointment of Dr. Jason J. Luke as Chief Medical Officer.

BiopharmaTrend
Aug 11th, 2025
Strand Therapeutics Secures $153 Million for Programmable mRNA Cancer Therapies

Kinnevik's Ala Alenazi, Ph.D., will join Strand's board of directors.

Crunchbase
Aug 8th, 2025
The Week's 10 Biggest Funding Rounds: Public Safety Leads, While Healthcare And Fintech Also See Big Deals

Strand Therapeutics, $153M, biotechnology: Boston-based Strand Therapeutics, a developer of mRNA-based therapeutics, raised $153 million in a Series B funding led by Kinnevik.

Business Wire
Aug 8th, 2025
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.

BioSpace
Aug 7th, 2025
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds

Strand Therapeutics on Thursday closed a $153 million series B round that will help it advance its pipeline of novel mRNA therapies for cancer and other chronic conditions.

INACTIVE